CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Overview | Financials
Company Name CytomX Therapeutics, Inc.
Symbol CTMX
Currency USD
Price 1
Market Cap 78,117,600
Dividend Yield 0%
52-week-range 0.98 - 5.85
Industry Biotechnology
Sector Healthcare
CEO Dr. Sean A. McCarthy D.Phil., DPHIL
Website https://www.cytomx.com

An error occurred while fetching data.

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for

Related Stocks

Achilles Therapeutics plc logo

Achilles Therapeutics plc

ACHL

1.045 USD

Selecta Biosciences, Inc. logo

Selecta Biosciences, Inc.

SELB

0.881 USD

Anixa Biosciences, Inc. logo

Anixa Biosciences, Inc.

ANIX

3.62 USD

Rezolute, Inc. logo

Rezolute, Inc.

RZLT

5.72 USD

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

13.81 USD

TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

2.99 USD

Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc.

TCRT

2.02 USD

Financials

Numbers are in millions USD

Numbers are in millions USD